GT Biopharma | December 23, 2020
GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology organization focused in on innovative treatments dependent on the Company's restrictive NK cell engager (TriKE™) innovation stage is satisfied to report the introduction of extra interval information results for the Company's lead therapeutic competitor, GTB-3550, for the treatment of high-risk myelodysplastic syndromes (HR-MDS).
Erica Warlick, M.D, Principal Investigator for the GTB-3550 clinical trial, introduced extra clinical data results with the treatment with HR-MDS persistent #7 of its TriKE™ GTB-3550 during the Q&A meeting following her introduction at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition.
Mr. Anthony Cataldo, the Chairman and Chief Executive Officer of GT Biopharma commented, "Our clinical data demonstrates that our proprietary TriKE™ (CD16/IL15/CD33), safely activated and harnessed the patient's native NK cell's cancer killing ability in a target-directed fashion without side effects. Which is not the case with highly expensive and intrusive supplemental NK cell therapies. We look forward to progressing to the next level."
Insilico Medicine | March 15, 2021
Insilico Medicine, an AI drug discovery company, reported that UCB will incorporate Insilico's Chemistry42™ into UCB's inward drug discovery pipeline. UCB's initial appropriation of Insilico Medicine's restrictive innovation will give UCB's researchers the capacity to plan novel hit compounds that fulfill various predefined boundaries quickly and smooth out lead enhancement. With the Chemistry42™ platform, UCB researchers will likewise lessen the endeavors and expenses commonly connected with the plan, testing and commercialization of new drugs. Chemistry42™ v1.0 will be modified and conveyed on UCB's cloud-based supercomputing infrastructure.
Chemistry42™ is an adaptable, easy to understand programming platform that incorporates man-made brainpower (AI) strategies with the fields of therapeutic and computational science for the plan of novel little atoms with client characterized druglike physicochemical properties. The platform is an adaptable conveyed web application equipped for running various assignments in equal very quickly. Container coordination and work process the executives consider unsurprising equipment freethinker asset distribution and the execution on one or the other cloud or neighborhood HPC infrastructures.
"UCB is one of the leading companies in small molecule drug discovery. It was their insight and approach at the forefront of this science that encouraged us to move into AI-powered chemistry over five years ago and it gives me great pleasure to see UCB among the launch partners of our Chemistry42 operating system," said Alex Zhavoronkov, Ph.D., CEO of Insilico Medicine.
"Insilico Medicine has been very responsive in this quickly developing area of science and we are delighted to be one of the launch partners for Chemistry42," Jiye Shi, Global Head of Computer-Aided Drug Design at UCB said. "Our hope is that this platform will further enhance the digital transformation of our drug discovery capabilities for the benefit of patients worldwide."
About Insilico Medicine
Insilico Medicine develops software that leverages generative models, reinforcement learning (RL), and other modern machine learning techniques to generate new molecular structures with specific properties. Insilico Medicine also develops software for the generation of synthetic biological data, target identification, and the prediction of clinical trial outcomes. The company integrates two business models: providing AI-powered drug discovery services and software through its Pharma.AI platform (www.insilico.com/platform/) and developing its pipeline of preclinical programs. The preclinical program is the result of pursuing novel drug targets and novel molecules discovered through its platforms. Since its inception in 2014, Insilico Medicine has raised over $52 million and received multiple industry awards.
UCB, Brussels, Belgium is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.
Novalis Biotech | July 01, 2021
Novalis Biotech, an early-stage venture capital investor in healthcare-related technology, announced today the completion of its €25 million second fund, the Novalis Biotech Acceleration Fund. The fundraising has included both new and returning investors. The second fund's investor base comprises institutional investors, including Participate Maatschappij Vlaanderen (PMV), family offices, and high-net-worth individuals (HNWIs).
The Biotech Acceleration Fund will continue to invest in start-up and scale-up companies that use "enabling technologies" to improve healthcare. Genomic and bioinformatics technologies, drug research and manufacturing tools, diagnostics, and personalized medicine are examples. The funds will be divided between early-stage incubation initiatives and late-stage acceleration programs. Grapheal and RheaVita have already made investments in the enabling technologies they are developing. Novalis will continue to use its strong network in the Benelux area and intends to expand its investments throughout Western Europe and the United States.
Novalis invests early and focuses on capital-light ideas where modest investments can generate substantial value using software, intellectual property, tools, and other enabling technologies that can transform healthcare. Novalis has a strong track record of turning ideas into profitable businesses by using extensive networks.
Novalis Fund 1 was established in September 2018 with a total capitalization of €4 million, which was invested in eight companies, the majority of which were located in the Benelux region. BioLizard, Cergentis, Enzyre, Epify, Fertiga, myNEO, and OHMX.bio are among them. A first exit occurred when doc.ai, a US portfolio company, was acquired by Sharecare as part of an IPO.
About Novalis Biotech Acceleration
Novalis Biotech is an early-stage venture capital investor in healthcare-revolutionizing technologies. The company's main competence is digitalization in the life sciences, focusing on capital-light "enabling technologies" such as bioinformatics, artificial intelligence, genomics, personalized medicine, research or manufacturing tools, and diagnostics.